prodige

Simulated data inspired from the PRODIGE trial comparing the survival of patients with metastatic pancreatic cancer
treated with FOLFIRINOX or gemcitabine .
<ul>
<li><code>id</code>: study participant.</li>
<li><code>treatment</code>: treatment arm: FOLFIRINOX (T) or gemcitabine (C).</li>
<li><code>OS</code>: time from inclusion (say diagnosis) to end of follow-up.</li>
<li><code>statusOS</code>: event triggering the end of follow-up: death (1), drop-out (0).</li>
<li><code>PFS</code>: time from inclusion (say diagnosis) to progression of the disease or end of follow-up.</li>
<li><code>statusPFS</code>: progression (1) or end of follow-up (0).</li>
<li><code>toxicity</code>: most serious side effect observed during the follow-up (1 mild, 6 severe).</li>
<li><code>sex</code>: male (M) or female (F)</li>
</ul>

datasets

Implementation of the Generalized Pairwise Comparisons (GPC) as defined in Buyse (2010) <doi:10.1002/sim.3923> for complete observations, and extended in Peron (2018) <doi:10.1177/0962280216658320> to deal with right-censoring. GPC compare two groups of observations (intervention vs. control group) regarding several prioritized endpoints to estimate the probability that a random observation drawn from one group performs better/worse/equivalently than a random observation drawn from the other group. Summary statistics such as the net treatment benefit, win ratio, or win odds are then deduced from these probabilities. Confidence intervals and p-values are obtained based on asymptotic results (Ozenne 2021 <doi:10.1177/09622802211037067>), non-parametric bootstrap, or permutations. The software enables the use of thresholds of minimal importance difference, stratification, non-prioritized endpoints (O Brien test), and can handle right-censoring and competing-risks.

Brice Ozenne

BuyseTest

Generalized Pairwise Comparisons

Eva Cantagallo

William Anderson

Julien Peron

Johan Verbeeck

prodige function

An object of class <code>data.table</code> (inherits from <code>data.frame</code>) with 823 rows and 8 columns.

Format

Author

RCT In Metastatic Pancreatic Cancer Comparing Two Chemoterapy. — prodige

RCT In Metastatic Pancreatic Cancer Comparing Two Chemoterapy.

prodige: RCT In Metastatic Pancreatic Cancer Comparing Two Chemoterapy.

Description

Usage

Arguments

Format

Author

References